Compare Natco Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA BIOCON NATCO PHARMA/
BIOCON
 
P/E (TTM) x 15.5 22.5 69.1% View Chart
P/BV x 3.1 3.0 102.4% View Chart
Dividend Yield % 1.1 0.4 284.7%  

Financials

 NATCO PHARMA   BIOCON
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
BIOCON
Mar-18
NATCO PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs8491,188 71.5%   
Low Rs557305 182.6%   
Sales per share (Unadj.) Rs573.868.7 835.0%  
Earnings per share (Unadj.) Rs176.07.6 2,330.6%  
Cash flow per share (Unadj.) Rs198.214.0 1,418.7%  
Dividends per share (Unadj.) Rs6.251.00 625.0%  
Dividend yield (eoy) %0.90.1 663.7%  
Book value per share (Unadj.) Rs842.786.3 976.0%  
Shares outstanding (eoy) m36.50600.00 6.1%   
Bonus/Rights/Conversions BBIS-  
Price / Sales ratio x1.210.9 11.3%   
Avg P/E ratio x4.098.9 4.0%  
P/CF ratio (eoy) x3.553.4 6.6%  
Price / Book Value ratio x0.88.6 9.6%  
Dividend payout %3.613.2 26.8%   
Avg Mkt Cap Rs m25,660447,900 5.7%   
No. of employees `0005.06.1 80.6%   
Total wages/salary Rs m3,5599,311 38.2%   
Avg. sales/employee Rs Th4,225.36,705.8 63.0%   
Avg. wages/employee Rs Th718.01,514.2 47.4%   
Avg. net profit/employee Rs Th1,295.9736.9 175.9%   
INCOME DATA
Net Sales Rs m20,94541,234 50.8%  
Other income Rs m1,3022,062 63.1%   
Total revenues Rs m22,24743,296 51.4%   
Gross profit Rs m7,9488,291 95.9%  
Depreciation Rs m8103,851 21.0%   
Interest Rs m193615 31.4%   
Profit before tax Rs m8,2475,887 140.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8231,569 116.2%   
Profit after tax Rs m6,4244,531 141.8%  
Gross profit margin %37.920.1 188.7%  
Effective tax rate %22.126.7 82.9%   
Net profit margin %30.711.0 279.1%  
BALANCE SHEET DATA
Current assets Rs m23,47241,486 56.6%   
Current liabilities Rs m7,28721,413 34.0%   
Net working cap to sales %77.348.7 158.7%  
Current ratio x3.21.9 166.3%  
Inventory Days Days9264 144.1%  
Debtors Days Days8894 93.7%  
Net fixed assets Rs m18,64850,661 36.8%   
Share capital Rs m3653,000 12.2%   
"Free" reserves Rs m34,52548,808 70.7%   
Net worth Rs m30,76051,808 59.4%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m43,03199,897 43.1%  
Interest coverage x43.710.6 413.6%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.4 117.9%   
Return on assets %15.45.2 298.5%  
Return on equity %20.98.7 238.8%  
Return on capital %27.49.6 284.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,53612,058 95.7%   
Fx outflow Rs m2,9397,348 40.0%   
Net fx Rs m8,5974,710 182.5%   
CASH FLOW
From Operations Rs m6,6886,621 101.0%  
From Investments Rs m-6,122-6,840 89.5%  
From Financial Activity Rs m-509-2,397 21.2%  
Net Cashflow Rs m66-2,612 -2.5%  

Share Holding

Indian Promoters % 52.0 40.4 128.8%  
Foreign collaborators % 1.5 20.6 7.1%  
Indian inst/Mut Fund % 7.8 8.4 93.3%  
FIIs % 16.6 10.7 155.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 19.9 130.7%  
Shareholders   25,395 109,995 23.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   WOCKHARDT  J.B.CHEMICALS  ORCHID PHARMA LTD  DIVIS LABORATORIES  FULFORD INDIA  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 15, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS